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Abstract
Background: The speed of flea knockdown by different products and their duration of effectiveness are factors
which affect veterinarian prescribing decisions. To further validate the month-long pulicidal effectiveness of
spinosad and determine its rate of flea knockdown to that of afoxolaner, three studies were conducted in two
laboratories in the United States, utilizing flea infestations from colonies which are regularly refreshed through
introduction of locally caught fleas.
Methods: All study assessors were blinded, dogs were ranked by pre-study flea counts and randomized accordingly,
and treatments administered on Day 0. All studies included a negative control group; two also included an afoxolaner
group. In one study, flea challenges for treated and control dogs (10 per group) were completed 21 and 28 days after
treatment and counts were performed 24 h later. In each of two speed-of-knockdown (SOK) studies, 36 dogs were
randomized, six dogs per group, to: untreated controls; administered oral afoxolaner (2.6-6.2 mg/kg); or oral spinosad
(32.1-59.2 mg/kg). In the SOK studies, live fleas from Day -1 infestations were counted after being combed off at 1 and
3 h after treatment, and after reinfestations on Day 7.
Results: There were no treatment-related adverse events. Spinosad was 98.6 % effective at 28 days post treatment.
For SOK, geometric mean live flea counts for afoxolaner were not different from controls at any assessment. For
spinosad, all mean counts were significantly lower than in controls (p≤ 0.0128) except at 1 h post treatment in both
studies. Spinosad was significantly more effective than afoxolaner in both studies at 3 h post treatment (p≤ 0.0065)
and post-Day 7 infestation (p≤ 0.0054), and at 1 h post treatment (p = 0.0276) and post-Day 7 infestation in one study.
Conclusions: These data validate spinosad’s faster onset of flea knockdown than afoxolaner against infestations
present at the time of treatment, and faster residual speed of flea knockdown for at least 7 days post treatment, and
confirm spinosad’s extended residual speed of kill for at least 28 days post treatment.
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Background
The widespread establishment of monthly treatments to
control canine parasites began in the 1980s and early
1990s with the release of the monthly orally administered
macrocyclic lactone products that produced a major ad-
vance in the prevention of heartworm disease. These
treatments also offered effectiveness against intestinal
nematode parasites. Subsequent to the emergence of these
products, monthly flea control became accepted in the
1990s with the release of the low volume topical flea con-
trol products containing imidacloprid or fipronil. The
monthly oral insect growth regulator (IGR) lufenuron,
which could prevent the hatching of viable larvae from flea
eggs was registered in 1994. A limitation of this, and IGRs
in general, is the absence of adult flea effectiveness, and
perhaps for this reason the topical flea adulticide knock-
down products dominated the market throughout the
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remainder of the decade and beyond. However, the regis-
tration in 2000 of nitenpyram highlighted the potential for
oral treatments. Nitenpyram provided a very rapid onset of
flea knockdown, and was demonstrated to kill more than
99 % of fleas within four to six hours of treatment.
Additionally, studies with nitenpyram demonstrated that
systemically acting pulicides could provide a faster onset of
action against fleas than topically applied products in dogs
and in cats [1–3]. The major limitation of nitenpyram was
its ultra short duration of action − little more than a day.
There was therefore a need for an oral product that would
quickly eliminate existing flea burdens and maintain flea
killing activity for a month, thereby aligning with the well-
established paradigm of monthly parasite control.
Spinosad was the first orally administered flea control
product to provide one month of residual adult flea
knockdown activity. With 100 % effectiveness reported
within 4 h of treatment of existing infestations, spinosad
was shown to have a comparable onset of activity to
nitenpyram, but also provided a duration of flea knock-
down that reduced flea egg output over one month by
>99.8 % [4]. Controlled field studies with spinosad re-
ported from 2007 through 2015 have confirmed its on-
going and consistent efficacy in field studies, achieving a
high level of flea control in households that included
treated dogs and cats, and alleviating the clinical signs of
flea infestation, including pruritus [5–10].
In recent years, a number of reports of purpose-designed
studies have suggested the flea activity of spinosad to be in-
consistent under laboratory conditions. These studies may
not be reflective of real world conditions because they have
used challenges with selected flea isolates such as the
Kansas 1 (KS1) strain [11, 12], maintained under laboratory
conditions since 1990, or laboratory-reared fleas from
Europe that were transported internationally for testing in
various contract testing laboratories [13, 14].
To further validate the month-long pulicidal effective-
ness of spinosad, and to determine the relative rate of flea
knockdown of spinosad to that of afoxolaner, the labora-
tory studies reported in this paper were undertaken using
fleas from colonies in which genetics are regularly modified
by the introduction of locally sourced wild-type fleas
(Ctenocephalidesfelis) to reflect potentially changing field
challenges. Afoxolaner is the second orally administered
systemically acting compound to be labeled for one month
of flea effectiveness. As earlier work had demonstrated that
spinosad was 100 % effective in four hours, the studies re-
ported herein compared the products at up to 3 h post
treatment or post-infestation on Day 7 [4].
Methods
Ethical approval
The studies summarized in this report were performed
at 2 independent laboratories in accordance with Good
Clinical Practices as described in VICH guideline GL9,
Good Clinical Practice (June 2000). All protocols were
reviewed and approved by the respective Institutional
Animal Care and Use Committee. One study utilized a
randomized block, blinded, parallel-arm, negative con-
trol design and two studies also included a positive
controlled group treated with afoxolaner. Individual
dogs were considered the experimental unit.
Flea infestations were completed using each laboratory’s
established in-house C. felis colonies to which recent iso-
lates obtained from a local source had been introduced
within 12 months of the beginning of each study. Ap-
proximately 100 unfed adult fleas were counted from the
colony into application vials and then deposited along the
dorsal mid-line, from the shoulder to hip, of each dog.
Each infested dog was then hand-restrained within its pri-
mary housing run for sufficient time to allow parasites to
penetrate the hair coat. Disposable gloves and aprons were
worn and changed between each of the treatment groups.
Staff performing the post-treatment flea comb counts
and making individual animal observations remained
blinded to the actual treatment groups. At the assigned
time points, fleas were removed and counted by thor-
oughly combing animals with fine-tooth flea combs. Flea
counts were completed using each facility’s standard oper-
ating protocol of thorough whole body combing of each
dog for at least 10 min, regularly removing fleas and hair
from the comb, determining whether or not fleas were
dead, showing abnormal movement (moribund but
counted as live), or live and apparently normal. Only live
fleas were counted and recorded, and any flea movement
was recorded as normal or abnormal. Fleas were discarded
after removal from a dog. Beyond the initial 10 min comb-
ing, if additional fleas were found combing was continued
for an additional five minutes until no additional fleas
were found. The fleas and hair were disposed of in con-
tainers of a soap solution. To avoid cross contamination,
each treatment group had new separate comb pairs
assigned to it. The group-assigned combs were rinsed with
alcohol and wiped clean between each animal. Disposable
gloves and aprons were worn and changed between each
of the treatment groups.
Experimental animals
A total of 92 purebred and mixed-breed dogs, at least
6 months old and weighing between 6.8 and 20.9 kg
were used in these studies. All dogs were owned by the
respective trial facility and had been present in the re-
spective study facility for at least one week and so were
well acclimated. Each dog was uniquely identified by ear
tattoo or by a subcutaneous microchip. No medications
or vaccinations had been given during the week prior to
initial study procedures. Water was provided ad libitum.
Dogs were fed according to the standard operating
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procedure of each facility and housed in cages of appro-
priate size that conformed to accepted guidelines for
animal welfare. To be eligible for inclusion in a study,
each dog was required to be healthy; to have retained at
least 50 fleas from a pre-study infestation of approxi-
mately 100 fleas applied 24 h earlier; to not have been
exposed to any oral or topical insecticide or IGRs within
100 days of being selected for each study; and to not be
used for breeding.
Design of studies
Efficacy at days 22 and 29 In this study, 24 dogs were
ranked on the basis of pre-study flea counts, and the
four dogs with the lowest flea burdens were eliminated.
The remaining 20 were randomized on the basis of the
pre-study counts to either of 2 groups, 10 dogs per
group: an untreated control group or a treated group, to
receive spinosad (Comfortis®, Elanco; minimum dose
30 mg/kg, United States label dose) according to label
recommendations. Dogs were returned to their kennels
and flea challenges were completed on Days 21 and 28.
Flea counts were completed 24 h after each infestation.
Spinosad/afoxolaner speed of flea knockdown studies
Studies were undertaken at two separate sites to determine
the speed of flea knockdown of spinosad (Comfortis) and
afoxolaner (NexGard®, Merial) against infestations present
at the time of treatment, and against flea challenge one
week after treatment. At one site 57 dogs were screened,
42 dogs at the second site. At each site, the 36 dogs with
the highest flea counts were included – the six with the
highest flea counts constituted Block 1; the next 6 Block 2,
etc., until 6 blocks were formed. Each dog from each block
was then randomly assigned to one of six groups until the
36 dogs were assigned to groups (Table 1).
Treatments were offered free choice in the palm of a
gloved right hand (the same type of glove for each dog; a
new glove for each dog). Treatments were recorded as
“Not accepted” if a dog accepted the product but then
ejected it unchewed or partially chewed, or if the dog
had not accepted the product free choice within 2 min
of it being offered. If the dog did not fully consume the
product within 2 min of it being offered, the dog was
pilled and recorded accordingly. All treatments were
commercially purchased and administered according to
label on Day 0 (spinosad minimum dose 30 mg/kg; afox-
olaner minimum dose 2.5 mg/kg).
Flea infestations on Day -1 were used to determine the
immediate knockdown and speed-of-kill of adult fleas
from the treatment administered on Study Day 0. Speed-
of-kill efficacy was also assessed on Study Day 7, based
on flea infestations made on that study day. The number
of live fleas combed off appropriate dogs was counted at
1 and 3 h after dosing on Study Day 0 and after infest-
ation on Study Day 7.
Assessment of effectiveness
In the study of efficacy at 22 and 29 days, the primary
hypothesis to be tested was:
H0: There will be no effect of spinosad on flea mortality
compared to control dogs.
Ha: Spinosad will provide significant reductions in live
flea counts, compared to controls.
In the speed of kill studies the primary hypothesis was:
H0: There will be no difference between groups in the
speed of flea knockdown.
Ha: Spinosad will provide significantly faster flea
knockdown than afoxolaner.
Descriptive statistics included geometric and arithmetic
mean numbers of live fleas (defined as: 1. fleas showing
normal movement; and, 2. fleas showing normal move-
ment plus moribund fleas as demonstrated by abnormal
movement). To calculate the percent efficacy at each time
point, the mean numbers of fleas on dogs in the untreated
control group were used for comparison to the flea counts
on dogs treated with the study products.
For calculation of geometric means by treatment
group at each time point, flea counts were transformed
to the natural logarithm of (count + 1) to account for
zero values, then back transformed to provide the final
value. Percentage efficacy of each treated group with re-
spect to the corresponding control group was calculated
using the formula below for each time point.
% Efficacy ¼ Mean live flea count for control group−Mean live flea count for treated group
Mean live flea count for control group
x 100
The log counts of the treated groups were compared
to the log counts of the untreated control group using
Table 1 Treatment groups and description of treatments and
flea countsa
Group Dose Rate (per label)
(all dogs in fed state)
A Spinosad, minimum
dose 30 mg/kg
1 hour after treatment (Day 0)
and post infestation (Day 7)
B Spinosad, minimum
dose 30 mg/kg
3 hours after treatment (Day 0)
and post infestation (Day 7)
C Afoxolaner minimum
dose 2.5 mg/kg
1 hour after treatment (Day 0)
and post infestation (Day 7)
D Afoxolaner minimum
dose 2.5 mg/kg
3 hours after treatment(Day 0)
and post infestation (Day 7)
E No treatment administered
F No treatment administered
aAll dogs were offered their daily ration within the one hour prior to treatment
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an F-test adjusted for the allocation blocks used to
randomize the animals to the treatment groups at each
time point separately. Separate calculations were com-
pleted for the number of live fleas (Normal + Abnormal)
and for the number of live Normal fleas. Statistical com-
parisons were completed of the percentage reduction
from control counts achieved at each time point by the
spinosad and afoxolaner treatments. All tests of signifi-
cance were performed at alpha = 0.05, 2-sided.
Results
There were no treatment-related adverse events observed
in any of the studies.
Efficacy at 22 and 29 days
The dose of spinosad administered to dogs ranged from
30.3 to 57.6 mg/kg (mean 45.0 mg/kg). For the counts
undertaken 24 h after the Day 21 infestation, there were
no normal fleas identified in the spinosad-treated dogs.
However, dead fleas were mistakenly included in abnormal
flea counts, thereby invalidating the total counts as a
means of assessing overall effectiveness. At 24 h after the
Day 28 infestation, geometric mean counts of live fleas
(showing normal movement plus abnormal, or moribund
fleas) completed 24 h after the Day 28 infestation were
89.4 in the control group (arithmetic mean 90.6), signifi-
cantly greater (p < 0.0001) than in the spinosad group,
1.28 (arithmetic mean 4.3) for a percentage reduction of
98.6 % (95.3 % based on arithmetic mean) (Table 2). In the
spinosad group, counts of moribund fleas in four dogs
were 3, 3, 5 and 7; no moribund fleas were found in con-
trol dogs. Based on counts of elimination of live fleas with
normal movement, spinosad effectiveness on Day 22 was
100 % and on Day 29 was 99.6 % (geometric means).
Speed of kill studies
In both studies combined, 22 of 24 spinosad group dogs
and 21 of 24 afoxolaner group dogs did not voluntarily
accept treatment and required pilling of the allocated
product. The dose rates for afoxolaner ranged from 2.6 to
6.2 mg/kg (means 4.0 mg/kg and 4.7 mg/kg) and of spino-
sad from 32.1 to 59.2 mg/kg (means 45.1 and 49.1 mg/kg).
In both studies arithmetic and geometric mean live flea
counts (fleas showing normal movement, plus moribund
fleas) in the spinosad groups were significantly lower than
in the control groups at all but the first assessment
(completed 1 h post treatment) (Tables 3 and 4). Com-
pared to the afoxolaner group, the percent effectiveness of
spinosad was significantly greater in both studies at 3 h
post treatment and at 1 and 3 h after the Day 7 infestation,
and at 1 h post treatment in Study 2 (Fig. 1). When mori-
bund fleas were excluded from counts (i.e., counted as
dead), most of the between-group statistical differences
are retained (Fig. 2) (Tables 5 and 6).
Afoxolaner comparisons to untreated controls, based
on geometric live flea counts, failed to achieve statisti-
cally significant reductions at all assessments. When
arithmetic mean live flea counts were calculated, the
only statistically significant differences between the afox-
olaner and control groups were on Day 7 at 3 h post in-
festation (Tables 3 and 4). At this time, arithmetic mean
reductions relative to controls were 22.2 % (p = 0.0188)
Table 4 Study 2: mean (standard error) (SE) live flea countsa of
control, afoxolaner and spinosad group dogs
Mean Control Afoxolaner Spinosad
Day 0 - 1 hour Geometric 81.2 (0.1) 86.0 (0.1) 71.0 (0.1)b
Arithmetic 81.8 (4.2) 86.3 (4.2) 71.8 (4.2)b
Day 0 - 3 hours Geometric 89.8 (0.5) 66.3 (0.5) 6.4 (0.5)c,d
Arithmetic 90.0 (7.3) 70.8 (7.3) 16.5 (7.3)c,d
Day 7 - 1 hour Geometric 91.2 (0.1) 88.9 (0.1) 38.1 (0.1)c,d
Arithmetic 91.5 (4.5) 89.2 (4.5) 41.5 (4.5)c,d
Day 7 - 3 hours Geometric 89.8 (0.6) 69.0 (0.6) 4.8 (0.6)c,d
Arithmetic 90.0 (5.4) 70.0 (5.4)e 16.2 (5.4)c,d
aIncludes moribund fleas, counted as live
Treated group different from control: cp ≤ 0.0007; ep = 0.0188
Different from afoxolaner: bp ≤ 0.0276; dp ≤ 0.0019
Table 3 Study 1: mean (standard error) (SE) live flea countsa of
control, afoxolaner and spinosad group dogs
Mean Control Afoxolaner Spinosad
Day 0 - 1 hour Geometric 82.5 (0.1) 90.6 (0.1) 85.1 (0.1)
Arithmetic 83.7 (3.8) 90.6 (3.8) 85.2 (3.8)
Day 0 - 3 hours Geometric 81.8 (0.2) 79.4 (0.2) 38.5 (0.2)b,c
Arithmetic 82.3 (6.7) 80.2 (6.7) 44.7 (6.7)b,c
Day 7 - 1 hour Geometric 95.3 (0.1) 83.7 (0.1) 75.2 (0.1)d
Arithmetic 95.5 (4.2) 84.0 (4.2) 76.5 (4.2)d
Day 7 - 3 hours Geometric 89.2 (0.4) 67.4 (0.4) 12.4 (0.4)e,f
Arithmetic 89.7 (4.9) 67.8 (4.9)e 21.0 (4.9)e,f
aIncludes moribund fleas, counted as live
Treated group different from control: bp ≤ 0.0051; dp ≤ 0.0128; ep = 0.0069
Different from afoxolaner: cp ≤ 0.0065; fp ≤ 0.0054
Table 2 Day 29 mean (standard error) (SE) live flea countsa and
percentage efficacy of spinosad
Control Spinosad
Geometric mean (SE) 89.4 (0.1) 1.3 (0.5)
% Efficacy - 98.6 %b
Arithmetic mean (SD) 90.6 (14.1) 4.30 (9.3)
% Efficacy - 95.3 %a
aMoribund fleas counted as live. bDifferent from control: p < 0.0001
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and 24.4 % (p = 0.0069). When moribund fleas were ex-
cluded from live flea counts, afoxolaner group geometric
mean counts were significantly lower than in the control
group 3 h after treatment on Day 0, when efficacy was
62.2 % (p = 0.0220) (Study 2) (Table 6; Fig. 2). There were
significant afoxolaner group reductions in arithmetic
means of 35.5 % (p = 0.0039) and 37.0 % (p < 0.0001), in
studies 1 and 2, respectively.
Discussion
These studies demonstrated that spinosad produces a
significantly faster flea knockdown than afoxolaner, and
that at the end of the month the effectiveness of spino-
sad is maintained. The results confirm earlier laboratory
work in pivotal dose confirmation studies for registra-
tion by the FDA, demonstrating that by killing fleas
before they can lay eggs, spinosad has the potential to
Fig. 2 Percent effectiveness, 1 and 3 h post treatment (Day 0) and post infestation (Day 7). Spinosad, Afoxolaner. Percentages based on
geometric mean live flea counts (normal fleas, excluding those showing abnormal movement) of each group compared to an untreated control
group. Different from control: ap = 0.0045; cp = 0.0133; dp = 0.0001; gp < 0.0001; jp = 0.0220. Different from afoxolaner: bp = 0.0059; ep = 0.0009;
fp = 0.0276; hp < 0.0001
Fig. 1 Percent effectiveness, 1 and 3 h post treatment (Day 0) and post infestation (Day 7). Spinosad, Afoxolaner. Percentages
based on geometric mean live flea counts (normal fleas including those showing abnormal movement) of each group compared to an
untreated control group. Different from control: ap = 0.0051; cp = 0.0128; dp = 0.0020; gp = 0.0007; jp = 0.0002; mp = 0.0006. Different from
afoxolaner: bp = 0.0065; ep = 0.0054; fp = 0.0276; hp = 0015; kp = 0.0002; np = 0.0015
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break the flea life cycle when used according to label.
This demonstration of the rapid onset of spinosad’s flea-
killing activity continues to align it with nitenpyram in
quickly eliminating flea infestations from infested dogs,
and in maintaining a superior speed of action to afoxola-
ner for at least one week after treatment. In assessing
the relevance of these laboratory studies to other re-
ported studies with spinosad, some considerations are
relevant.
First, in each of the studies reported in this paper, the
fleas used to infest dogs were laboratory-reared from
each research facility’s flea colonies which are regularly
refreshed with locally sourced wild-type fleas. This is in
contrast to other reported studies in which long-
established laboratory strains are selected and used re-
peatedly to demonstrate a lack of effectiveness that ap-
pears to be at variance with real world findings.
Second, those laboratory studies conflict with real-
world evidence. For instance, two reports of such
experimental studies found that fipronil and selamectin
were significantly more effective than spinosad [12, 15].
Yet, when spinosad was compared to these products in
field studies in Europe and the United States, not only
was spinosad’s effectiveness remarkably high following
each of two or three monthly treatments, but it was sig-
nificantly more effective than either of these topically
applied products [5–7]. In those field studies spinosad
also produced a better result in alleviating pruritus and
other signs of flea allergy dermatitis. It is therefore clear
that the laboratory-derived suggestion that the reported
topically applied products were more effective than spi-
nosad is soundly contradicted by field data that demon-
strate the reverse. Moreover, the concept of spinosad
variability arising from laboratory studies conflicts with
the consistency spinosad has shown in field studies. In
fact, spinosad appears to be unique among flea control
products in showing >99 % effectiveness in a number of
separate multi-clinic studies across Europe and the
United States in which the product was administered
monthly by dog owners [5–10].
Thus, while laboratory studies provide a useful means
of assessing a product’s potential utility, they may not be
reflective of real world results and the ultimate test of
any product is how well it performs in the hands of the
veterinary client.
Conclusion
Two laboratory studies demonstrated a superior speed
of action of orally administered spinosad compared to
afoxolaner at 1 and 3 h post treatment of existing flea
infestations, and after a flea challenge at seven days post
treatment. A separate study demonstrated that spinosad
continues to maintain a high level of residual flea kill
through four weeks after treatment. Taken together,
these results align with findings from field studies in
which monthly treatments with spinosad have provided
consistent flea control, along with associated benefits of
alleviation in flea-related pruritus.
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Table 6 Study 2: mean (standard error) (SE) live flea countsa of
control, afoxolaner and spinosad group dogs
Mean Control Afoxolaner Spinosad
Day 0 - 1 hour Geometric 81.2 (0.1) 86.0 (0.1) 71.0 (0.1)
Arithmetic 81.8 (4.2) 86.3 (4.2) 71.8 (4.2)b
Day 0 - 3 hours Geometric 89.8 (0.3) 33.9 (0.3)c 0.0 (0.0)d,e
Arithmetic 90.0 (9.6) 51.2 (9.6)c 0.0 (0.0)d,e
Day 7 - 1 hour Geometric 89.9 (0.4) 88.9 (0.4) 4.0 (0.4)d,e
Arithmetic 90.3 (3.9) 89.2 (3.9) 9.5 (3.9)d,e
Day 7 - 3 hours Geometric 89.8 (0.1) 54.3 (0.1)f 0.0 (0.6)d,e
Arithmetic 89.8 (0.1) 56.7 (4.1)f 0.0 (0.0)d,e
aCounts of live fleas with normal movement; excludes those with abnormal
movement, classified as moribund
Treated group different from control: cp ≤ 0.0220; dp < 0.0001; fp ≤ 0.0006
Different from afoxolaner: bp = 0.0276; ep < 0.0001
Table 5 Study 1: mean (standard error) (SE) live flea countsa of
control, afoxolaner and spinosad group dogs
Mean Control Afoxolaner Spinosad
Day 0 - 1 hour Geometric 81.0 (0.1) 90.6 (0.1) 85.1 (0.1)
Arithmetic 82.7 (4.3) 90.8 (4.3) 85.2 (4.3)
Day 0 - 3 hours Geometric 81.8 (0.3) 76.7 (0.3) 18.4 (0.3)b,c
Arithmetic 82.3 (6.1) 77.7 (6.1) 27.8 (6.1)b,c
Day 7 - 1 hour Geometric 95.3 (0.1) 83.7 (0.1) 70.8 (0.1)d
Arithmetic 95.5 (4.2) 84.0 (4.7) 72.8 (4.7)d
Day 7 - 3 hours Geometric 88.8 (0.4) 49.1 (0.4) 5.4 (0.4)e,f
Arithmetic 89.3 (6.6) 57.7 (6.6)g 8.5 (6.6)e,f
aCounts of live fleas with normal movement; excludes those with abnormal
movement, classified as moribund
Treated group different from control: bp ≤ 0.0045;
dp ≤ 0.0133;ep ≤ 0.0001; gp = 0.0039
Different from afoxolaner: cp ≤ 0.0001; fp ≤ 0.0054
Snyder et al. Parasites & Vectors  (2015) 8:578 Page 6 of 7
Received: 3 September 2015 Accepted: 4 November 2015
References
1. Dryden MS, Magid-Denenberg T, Bunch S, Boyer J, Schenker R. Control of
fleas on dogs and cats and in homes with the combination of oral
lufenuron and nitenpyram. Vet Ther. 2001;2(3, Summer):208–14.
2. Dryden MW, McCoy CM, Payne PA. Speed of flea kill with nitenpyram
tablets compared to imidacloprid spot on and fipronil spot on in dogs.
SupplCompendContinEducPract Vet. 2001;23(3A):24–7.
3. McCoy C, Broce AB, Dryden MW. Flea blood feeding patterns in cats treated
with oral nitenpyram and the topical insecticides imidacloprid, fipronil and
selamectin. Vet Parasitol. 2008;156:293–301.
4. Blagburn BL, Young DR, Moran C, Meyer JA, Leigh-Heffron A, Paarlberg T, et
al. Effects of orally administered spinosad (Comfortis) in dogs on adult and
immature stages of the cat flea (Ctenocephalidesfelis). Vet Parasitol.
2010;168:312–7.
5. Robertson-Plouch C, Baker KA, Hozak RR, Zimmermann AG, Parks SC, Herr C,
et al. Clinical field study of the safety and efficacy of spinosad chewable
tablets for controlling fleas on dogs. Vet Ther. 2008;9:26–36.
6. Wolken S, Franc M, Bouhsira E, Wiseman S, Hayes B, Schnitzler B, et al.
Evaluation of spinosad for the oral treatment and control of flea infestations
on dogs in Europe. Vet Rec. 2012;170:99–103.
7. Dryden MW, Ryan WG, Bell M, Rumschlag AJ, Young LM, Snyder DE.
Assessment of owner-administered monthly treatments with oral spinosad
or topical spot-on fipronil/(S)-methoprene in controlling fleas and
associated pruritus in dogs. Vet Parasitol. 2013;191:340–6.
8. Freedom of Information Summary. Original New Animal Drug Application
(NADA 141-406). NEXGARD Afoxolaner Chewable Tablet Dogs. Date of
Approval: September 14, 2013.
9. Meadows C, Guerino F, Sun F. A randomized, blinded, controlled USA field
study to assess the use of fluralaner tablets in controlling canine flea
infestations. Parasit Vectors. 2014;7:375.
10. Saridomichelakis MN, Chatzis MK, Petanides T, Papadopoulos E. A field trial
of spinosad for the treatment and prevention of flea infestation in shepherd
dogs living in close proximity to flea-infested sheep. Parasit Vectors.
2015;8:324.
11. Dryden MW, Payne PA, Vicki S, Kobuszewki D. Efficacy of topically applied
dinotefuran formulations and orally administered spinosad tablets against
the KS1 flea strain infesting dogs. J Appl Res Vet Med. 2011;9(2):123–28.
12. Dryden MW, Payne PA, Smith V, Berg TC, Lane M. Efficacy of selamectin,
spinosad, and spinosad/milbemycin oxime against the KS1
Ctenocephalidesfelisflea strain infesting dogs. Parasit Vectors. 2013.
doi:10.1186/1756-3305-6-80.
13. Ross DH, Arther RG, von Simson C, Doyle V, Dryden MW. Evaluation of the
efficacy of topically administered imidacloprid + pyriproxyfen and orally
administered spinosad against cat fleas (Ctenocephalidesfelis): impact of
treated dogs on flea life stages in a simulated home environment. Parasit
Vectors. 2012. doi:10.1186/1756-3305-5-192.
14. Varloud M, Fourie JJ, Blagburn BL, Deflandre A. Expellency, anti-feeding and
speed of kill of a dinotefuran-permethrin-pyriproxyfen spot-on (Vectra®3D)
in dogs weekly challenged with adult fleas (Ctenocephalidesfelis) for 1
month-comparison to a spinosad tablet (Comfortis®). Parasitol Res. 2015.
doi:10.1007/s00436-015-4470-7.
15. Beugnet F, Doyle V, Murray M, Chalvet-Monfray K. Comparative efficacy on
dogs of a single topical treatment with the pioneer fipronil/(S)-methoprene
and an oral treatment with spinosad against Ctenocephalidesfelis. Parasite.
2011;18:325–31.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Snyder et al. Parasites & Vectors  (2015) 8:578 Page 7 of 7
